SOURCE: StockCall

StockCall

April 27, 2011 09:36 ET

Equity Research on Valeant Pharmaceuticals International and Hospira Inc. - Demand, Approval and Takeovers Dominate Drug Delivery

JOHANNESBURG, SOUTH AFRICA--(Marketwire - Apr 27, 2011) - www.stockcall.com/ offers investors comprehensive research on the Drug Delivery industry and has completed analytical research on Valeant Pharmaceuticals International (NYSE: VRX) and Hospira Inc. (NYSE: HSP). Register with us today at www.stockcall.com/ to have free access to these researches.

Companies in the Drug Delivery Industry have had a lot on their plate recently, as approval for new drugs as well as increased demand for established ones have kept things interesting. Demand for the leukemia drug cytarabine has been intense recently, as two of the companies that manufacture it have had production problems. Register now at https://stockcall.com/development/stockcall/page.php?name=register.html to have free access to our reports on the Drug Delivery industry.

www.stockcall.com/ is an online platform where investors doing their due-diligence on the Drug Delivery industry can have easy and free access to our analyst research and opinions on Valeant Pharmaceuticals International and Hospira Inc.; investors and shareholders of these companies can simply register for a complimentary membership at https://stockcall.com/development/stockcall/page.php?name=register.html

Getting the active ingredient has proven troublesome in the past, and some shipments were more recently stopped due to quality shortcomings. Hospira Inc. is one such company that is manufacturing the drug, and has reported that they will be increasing production to try and deal with the undersupply. Hospira Inc. research report is available for free by signing up now at www.stockcall.com/HSP270411.pdf.

While some companies battle production issues, others have been looking to mergers and acquisitions, as well as drug approval to increase their market share. In Europe, Valeant Pharmaceuticals International together with Glaxo SmitheKline recently got approval for their epilepsy drug Trobalt. Valeant has also been active in the acquisitions arena, and the company has been trying to acquire Cephalon Inc. Valeant Pharmaceuticals International research report is accessible for free by registering today at www.stockcall.com/VRX270411.pdf.

Visit www.stockcall.com/ to see how companies in this industry have grown over the past years and how they are expected to perform in the future.

About StockCall.com
StockCall.com is a financial website where investors can have easy, precise and comprehensive research and opinions on stocks making the headlines.

Contact Information